Cargando…
DDEL-04. Pharmacokinetic/Pharmacodynamic analysis of the DNA methyltransferase inhibitor 5-azacytidine shows adequate brain tissue penetration with intravenous administration in a DIPG mouse patient-derived xenograft model.
One of the biggest obstacles in developing effective therapies for CNS tumors is drug delivery due to the enigmatic challenge of penetrating the blood-brain barrier. 5-azacytidine is a DNA methyltransferase inhibitor which was the first epigenetic targeting chemotherapeutic approved by the FDA. Alte...
Autores principales: | Groves, Andrew, Jones, Kristen, Cameron, Amy, Panditharatna, Eshini, Morrow, Murry, Mozarsky, Brett, McCully, Cynthia, Peer, Cody, De Nguyen, Quang-, Filbin, Mariella, Warren, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164756/ http://dx.doi.org/10.1093/neuonc/noac079.125 |
Ejemplares similares
-
DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Ung, Caitlin, et al.
Publicado: (2020) -
DDEL-04. ENGINEERED NANOCARRIERS TO ENHANCE DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
por: Straehla, Joelle P, et al.
Publicado: (2020) -
DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
por: Lau, Grace, et al.
Publicado: (2020) -
DDEL-02. Intra-arterial Delivery for Novel Combinatorial Chemotherapies in Choroid Plexus Carcinoma
por: Martin, Brice, et al.
Publicado: (2022) -
DDEL-01. ENHANCING DRUG DELIVERY WITH MRgFUS FOR DIFFUSE INTRINSIC PONTINE GLIOMA MODEL
por: Ishida, Joji, et al.
Publicado: (2020)